These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20740314)

  • 1. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.
    Roy KK; Singh S; Saxena AK
    Mol Divers; 2011 May; 15(2):477-89. PubMed ID: 20740314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
    Saxena S; Chaudhaery SS; Varshney K; Saxena AK
    SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    J Biomol Struct Dyn; 2018 May; 36(6):1463-1478. PubMed ID: 28482755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
    Saxena AK; Saxena S; Chaudhaery SS
    SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods.
    Liu J; Wang F; Ma Z; Wang X; Wang Y
    Int J Mol Sci; 2011 Jan; 12(2):946-70. PubMed ID: 21541036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening.
    Ballante F; Caroli A; Wickersham RB; Ragno R
    J Chem Inf Model; 2014 Mar; 54(3):956-69. PubMed ID: 24564321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
    Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
    Kumar BV; Kotla R; Buddiga R; Roy J; Singh SS; Gundla R; Ravikumar M; Sarma JA
    J Mol Model; 2011 Jan; 17(1):151-63. PubMed ID: 20393763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
    Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
    J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Approaches for the Design of Novel Anticancer Compounds Based on Pyrazolo[3,4-d]pyrimidine Derivatives as TRAP1 Inhibitor.
    Ali A; Abdellattif MH; Ali A; AbuAli O; Shahbaaz M; Ahsan MJ; Hussien MA
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into designing the dual-targeted HER2/HSP90 inhibitors.
    Chen CY; Chen CY
    J Mol Graph Model; 2010 Aug; 29(1):21-31. PubMed ID: 20471294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening.
    Jia J; Xu X; Liu F; Guo X; Zhang M; Lu M; Xu L; Wei J; Zhu J; Zhang S; Zhang S; Sun H; You Q
    PLoS One; 2013; 8(4):e59315. PubMed ID: 23565147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.